Abstracts tagged "Granulomatosis with Polyangiitis (GPA)"

Abstract Number: 0718 • ACR Convergence 2025
Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden
Hanna Lindberg¹, Klytaimnistra Voudouri¹, Lars Lindhagen¹, Maria K Svensson², Ann Knight¹ and Johanna Dahlqvist³, ¹Uppsala University, Uppsala, Sweden, ²Uppsala University, Uppsala, ³Uppsala University Hospital, Uppsala, Sweden
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk…
Abstract Number: 0713 • ACR Convergence 2025
Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
Adil Vural¹, Chao Zhang², Yaseen Kinanah¹, Cassandra Calabrese³ and Adam Brown⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland Heights, OH, ³Cleveland Clinic Foundation, Cleveland Heights, OH, ⁴Cleveland Clinic, Shaker Heights, OH
Background/Purpose: ANCA associated vasculitis (AAV) is a severe autoimmune disorder with substantial morbidity and mortality. Establishing the diagnosis might be challenging due to the existence…
Abstract Number: 0726 • ACR Convergence 2025
Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
Sebastian E Sattui¹, Elizabeth Ibiloye², Niranjan Kathe³, Sam Oh⁴, Virginia Noxon-Wood⁵, Iman Mohammadi⁵, Laura Moore-Schiltz⁵ and Tingting Li⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc, San Diego, CA, ⁴Amgen Inc, South San Francisco, CA, ⁵Inovalon, Bowie, MD, ⁶Washington University School of Medicine, St. Louis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the most common types of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Treatment-related toxicities, particularly from glucocorticoid…
Abstract Number: 1766 • ACR Convergence 2025
Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
caterina ricordi¹, Maxime Beydon², Johanne Liberatore³, Pascal Cohen⁴, bertrand Dunogue⁵, Camille Mettler⁶, Benjamin Torreau⁷, Luc Mouthon⁵, Xavier Puéchal⁸ and Benjamin Terrier⁹, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Sorbonne University, INSERM, Institut Pierre Louis of Epidemiology and Public Health, Equipe PEPITES, Pitié Salpêtrière Hospital, Service of Public Health, Centre of Pharmacoepidemiology (Cephepi), Paris, France, ³Department of Internal Medicine, Centre Hospitalier d’Angouleme, Angouleme, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁶Department of Internal Medicine, Hôpital Bichat - Claude-Bernard, Paris, France, ⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁹Cochin Hospital, Paris, France
Background/Purpose: Rituximab (RTX) is the standard of care for both induction and maintenance in ANCA-associated vasculitides (AAVs). While CD19 B-cell monitoring is used to evaluate…
Abstract Number: 1764 • ACR Convergence 2025
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Naomi Patel¹, Aaron Wu², Eli Miloslavsky³, Peter Merkel⁴, John Stone⁵, Hyon K. Choi⁶, Zachary Wallace³ and Emily Hyle², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Evaluating the effectiveness and safety profile of treatment strategies for the induction of remission of individuals with newly diagnosed AAV is important for guiding…
Abstract Number: 1609 • ACR Convergence 2025
A Multicenter Prospective Longitudinal Observational Study To Determine Safety Of Extended Treatment With Rituximab In Maintaining Remission In Patients With ANCA Associated Vasculitis (AAV) – An Interim Analysis
Ravi Kumar U¹, Anoop Chitrabhanu², Ramya Janardana³, Avinash Jain⁴, Nitty Mathews⁵, Rutvi Dave⁵, Prabhu Vasantha Kumar⁶, ashish mathew⁵, john mathew⁵, Prasanna Samuel⁵, Arul Rajamurugan², Vineeta Shobha³ and ruchika goel⁵, ¹Christian Medical college, Vellore, India, Bengaluru, Karnataka, India, ²Madras Medical College, Chennai, India, Chennai, Tamil Nadu, India, ³St. John’s Medical College, Bengaluru , India, Bangalore, Karnataka, India, ⁴SMS Medical College and Hospital, Jaipur, India, JAIPUR, Rajasthan, India, ⁵Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ⁶Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India
Background/Purpose: Rituximab (RTX) has been shown to achieve high remission-induction and sustained maintenance rates across multiple studies and clinical trials in patients with AAV. The…
Abstract Number: 1607 • ACR Convergence 2025
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Natasha Le Blanc¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Nataliya Milman⁹, Medha Soowamber¹⁰, Nader Khalidi¹¹, Christian Pagnoux¹⁰, Rosalie-Selene Meunier¹², Jan Willem Cohen Tervaert⁴, Elaine Yacyshyn⁴ and Arielle Mendel¹³, ¹McGill University, Montreal, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Self employed, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Universite de Montreal, Montreal, Canada, ⁹the Ottawa Hospital, Ottawa, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Hopital du Sacre-Coeur-de-Montreal, Montreal, QC, Canada, ¹³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Antibiotic prophylaxis is recommended during initial treatment of ANCA-associated vasculitis (AAV). We assessed characteristics associated with prophylaxis within a Canadian multicenter AAV cohort starting…
Abstract Number: 1606 • ACR Convergence 2025
One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System
Naomi Patel¹, Andrew King², Madison Negron³, Zachary Williams⁴, Ana Fernandes¹, Nora Shepherd², Colebrooke Johnson¹, Guy Katz¹, Belen Arevalo Molina¹, Elizabeth Ibiloye⁵, Sam Oh⁶, Zachary Wallace⁷ and Sebastian H Unizony⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Harvard Extension School, Medford, MA, ⁴Massachusetts General Hospital, Nancy, KY, ⁵Amgen Inc, Thousand Oaks, CA, ⁶Amgen Inc, South San Francisco, CA, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Avacopan has been approved for adjunctive use in adults with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the US. Here…
Abstract Number: 1598 • ACR Convergence 2025
Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
caterina ricordi¹, elena treppo², Pavel Novikov³, Paul Russo⁴, Luca moroni⁵, Angelo Fassio⁶, Paolo Delvino⁷, hervé lobbes⁸, Chiara Marvisi¹, Francesco Muratore¹, Xavier Puéchal⁹, Carlo Salvarani¹ and Benjamin Terrier¹⁰, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³Sechenov University, Moscow, Russia, ⁴Royal Adelaide Hospital, Clinical Immunology and Allergy, Adelaide, Australia, ⁵IRCCS San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy, ⁶University of Verona, Department of Medicine, Unit of Rheumatology, Verona, Italy, ⁷University of Milano-Bicocca, Monza, Monza and Brianza, Italy, ⁸Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: Medium- and small-vessel vasculitides (MVV and SVV) are a heterogeneous group of inflammatory diseases affecting the vascular wall. Current treatment strategies are based on…
Abstract Number: 1596 • ACR Convergence 2025
GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency
Brendan Denvir¹, Alexander Hillel², Ami Shah³, Ji Soo Kim¹, Philip Seo² and Brendan Antiochos⁴, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins, CLARKSVILLE, MD
Background/Purpose: Granulomatosis with polyangiitis (GPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis that affects all levels of the respiratory tract. Tracheobronchial stenosis (TBS) occurs in…
Abstract Number: 1595 • ACR Convergence 2025
Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis
Brendan Denvir¹, Brendan Antiochos², Philip Seo³ and Alexander Hillel³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins, CLARKSVILLE, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Subglottic stenosis (SGS) is a recognized manifestation of granulomatosis with polyangiitis (GPA), occurring in 8–23% of patients. A distinct variant, identified in this study,…
Abstract Number: 0721 • ACR Convergence 2025
Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Mats Junek¹, Sara Choi², Stephanie Garner³, Saara Rawn⁴, David Cuthbertson⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Ulrich Specks¹³, Kenneth Warrington¹³, Gerard Cox¹, Nader Khalidi¹⁴ and Peter Merkel⁸, ¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ²Queen's University, Kingston, ON, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴NOSM School of Medicine, Sudbury, ON, Canada, ⁵University of South Florida, Tampa, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴McMaster University, Hamilton, ON, Canada
Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…
Abstract Number: 2181 • ACR Convergence 2024
Large Pediatric Cohort with ANCA-associated Vasculitis at a Single Institution: Patient Characteristics, Clinical Course, and Outcomes
Jessica Bloom¹, Anna Monley², Sarah Reingold³, Robert Fuhlbrigge¹ and Peter Merkel⁴, ¹University of Colorado, Denver, CO, ²University of Colorado, Aurora, CO, ³Denver Health, Denver, CO, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an understudied, chronic inflammatory disease in children with significant morbidity and mortality. There are few large pediatric cohorts…
Abstract Number: 2478 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Christian Pagnoux¹, Antoine Neel², Sarah Bray³, Rachel E. Gurlin⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Internal Medicine, CHU Nantes, Nantes, France, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
Abstract Number: 2480 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
Robert Spiera¹, Robert Lebovics², Sarah Bray³, Rachel E. Gurlin⁴, David Jayne⁵ and Peter Merkel⁶, and ADVOCATE Study Group, ¹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²Hackensack Meridian University Health System, Hackensack, NJ, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].